IDSA 2020 Guidelines Provide Guidance on Antimicrobial Resistant Gram-Negative Infections

Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections.

In an interview with Pharmacy Times, Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections. The guidelines were reviewed in a session at the American Society of Health-System Pharmacists titled "Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline."

In part 1 of the discussion, Lodise said the IDSA guidance is designed to be an alternative and complementary document to comprehensive clinical guidelines. In the interview, Lodise also discussed how the guidance could inform current practice standards, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.